{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T14:10:52Z","timestamp":1753884652683},"reference-count":17,"publisher":"Informa Healthcare","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1517\/13543784.2012.696611","type":"journal-article","created":{"date-parts":[[2012,6,13]],"date-time":"2012-06-13T11:17:11Z","timestamp":1339586231000},"page":"1235-1239","source":"Crossref","is-referenced-by-count":22,"title":["More light at the end of the tunnel \u2013 apixaban in atrial fibrillation"],"prefix":"10.1517","volume":"21","author":[{"given":"Sheila A","family":"Doggrell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3197","published-online":{"date-parts":[[2012,6,13]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.019893"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1994.00420130036007"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000121736.16643.11"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199011293232201"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1378\/chest.119.1_suppl.22S"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.3.331"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.2174\/157488711795177921"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107039"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2009.08.026"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007432"},{"key":"CIT0012","author":"Diener HC","year":"2012","journal-title":"Lancet Neurol"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105819"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1112500"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1109748"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1112812"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.029017"},{"key":"CIT0019","author":"Deitelzweig S","year":"2012","journal-title":"J Med Econ"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/13543784.2012.696611","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,12,13]],"date-time":"2016-12-13T13:16:17Z","timestamp":1481634977000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.1517\/13543784.2012.696611"}},"subtitle":["Evaluation of Granger CB, Alexander JH, McMurray JJV et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011, 365:981-92 and Connolly SJ Eikelboom J, Joyner C et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011, 364:806-17."],"short-title":[],"issued":{"date-parts":[[2012,6,13]]},"references-count":17,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2012,7,12]]},"published-print":{"date-parts":[[2012,8]]}},"alternative-id":["10.1517\/13543784.2012.696611"],"URL":"https:\/\/doi.org\/10.1517\/13543784.2012.696611","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,13]]}}}